Clinical Pharmacology and Therapeutics - Table of Contents alert Volume 90 Issue 5

TABLE OF CONTENTS Volume 90, Issue 5 (November 2011) In this issue In This Issue Editorial News & Views Perspectives State of the Art Research Discovery & Development Also new AOP Advertisement Myriad RBM's Comprehensive Protein Biomarker Solutions, helping turn biomarker studies into Biomarker Breakthroughs. From concept through clinical trial, Myriad RBM has the biomarkers, the platform and the expertise to guide your biomarker strategy. Click Here to learn more. Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Explore superior mAb recovery. For scientists working in early mAb discovery, the fully automated Agilent AssayMAP Bravo platform provides the highest antibody recovery possible. Parallel processing means you'll handle more samples in less time, with a demonstrated mAb recovery of 83% or greater. Watch interview and see the proof.   In This Issue Top IN THIS ISSUE In This Issue Clin Pharmacol Ther 2011 90: 635; 10.1038/clpt.2011.233 Full Text Editorial Top EDITORIAL Placebo in Clinical Trials S Ito Clin Pharmacol Ther 2011 90: 637-639; 10.1038/clpt.2011.230 Full Text News & Views Top HIGHLIGHTS Highlights Clin Pharmacol Ther 2011 90: 640-641; 10.1038/clpt.2011.234 Full Text ASCPT NEWS ASCPT News Clin Pharmacol Ther 2011 90: 642-644; 10.1038/clpt.2011.205 Full Text Perspectives Top COMMENTARIES Integration of Diverse Data Sources for Prediction of Adverse Drug Events D R Abernethy, J P F Bai, K Burkhart, H-G Xie and P Zhichkin Clin Pharmacol Ther 2011 90: 645-646; 10.1038/clpt.2011.171 Abstract | Full Text Registration of Observational Studies Does Not Enhance Validity D A Savitz Clin Pharmacol Ther 2011 90: 646-648; 10.1038/clpt.2011.199 Abstract | Full Text LETTERS TO THE EDITOR Commercial Factors Override Science in Combination Addiction Drug Trial A Byrne Clin Pharmacol Ther 2011 90: 649; advance online publication, September 28, 2011; 10.1038/clpt.2011.166 Full Text Response to “Commercial Factors Override Science in Combination Addiction Drug Trial” E C Strain, J A Harrison and G E Bigelow Clin Pharmacol Ther 2011 90: 650; advance online publication, September 28, 2011; 10.1038/clpt.2011.198 Full Text State of the Art Top STATE OF THE ART Hidden Administration of Drugs F Benedetti, E Carlino and A Pollo Clin Pharmacol Ther 2011 90: 651-661; advance online publication, October 12, 2011; 10.1038/clpt.2011.206 Abstract | Full Text Research Top REPORTS Linking Pharmacology to Clinical Reports: Cyclobenzaprine and Its Possible Association With Serotonin Syndrome J Mestres, S A Seifert and T I Oprea Clin Pharmacol Ther 2011 90: 662-665; advance online publication, October 5, 2011; 10.1038/clpt.2011.177 Abstract | Full Text ARTICLES Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy S Katzenmaier, C Markert, K-D Riedel, J Burhenne, W E Haefeli and G Mikus Clin Pharmacol Ther 2011 90: 666-673; advance online publication, September 21, 2011; 10.1038/clpt.2011.164 Abstract | Full Text A Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to Metformin J H Choi, S W Yee, A H Ramirez, K M Morrissey, G H Jang, P J Joski, J A Mefford, S E Hesselson, A Schlessinger, G Jenkins, R A Castro, S J Johns, D Stryke, A Sali, T E Ferrin, J S Witte, P-Y Kwok, D M Roden, R A Wilke, C A McCarty, R L Davis and K M Giacomini Clin Pharmacol Ther 2011 90: 674-684; advance online publication, September 28, 2011; 10.1038/clpt.2011.165 Abstract | Full Text Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of JNJ-38431055, a Novel GPR119 Receptor Agonist and Potential Antidiabetes Agent, in Healthy Male Subjects L B Katz, J J Gambale, P L Rothenberg, S R Vanapalli, N Vaccaro, L Xi, D C Polidori, E Vets, T C Sarich and P P Stein Clin Pharmacol Ther 2011 90: 685-692; advance online publication, October 5, 2011; 10.1038/clpt.2011.169 Abstract | Full Text Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age Z Desta, Y Kreutz, A T Nguyen, L Li, T Skaar, L K Kamdem, N L Henry, D F Hayes, A M Storniolo, V Stearns, E Hoffmann, R F Tyndale and D A Flockhart Clin Pharmacol Ther 2011 90: 693-700; advance online publication, October 5, 2011; 10.1038/clpt.2011.174 Abstract | Full Text A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy P J Avery, A Jorgensen, A K Hamberg, M Wadelius, M Pirmohamed and F Kamali on behalf of the EU-PACT Study Group Clin Pharmacol Ther 2011 90: 701-706; advance online publication, September 28, 2011; 10.1038/clpt.2011.186 Abstract | Full Text Acetaminophen Metabolism After Major Surgery: A Greater Challenge With Increasing Age G Pickering, E Schneider, I Papet, E Pujos-Guillot, B Pereira, E Simen, C Dubray and P Schoeffler Clin Pharmacol Ther 2011 90: 707-711; advance online publication, October 5, 2011; 10.1038/clpt.2011.176 Abstract | Full Text Genetic Variants of Interferon-Stimulated Genes and IL-28B as Host Prognostic Factors of Response to Combination Treatment for Chronic Hepatitis C R Lopez-Rodriguez, M Trapero-Marugan, M J Borque, M Roman, A Hernandez-Bartolome, Y Rodriguez-Muñoz, S Martin-Vilchez, F Abad-Santos, P Muñoz de Rueda, J R Vidal-Castiñeira, L Rodrigo, J Salmeron, R Moreno-Otero and P Sanz-Cameno Clin Pharmacol Ther 2011 90: 712-721; advance online publication, October 12, 2011; 10.1038/clpt.2011.189 Abstract | Full Text Discovery & Development Top DISCOVERY Mechanisms Involved in Placebo and Nocebo Responses and Implications for Drug Trials W Rief, U Bingel, M Schedlowski and P Enck Clin Pharmacol Ther 2011 90: 722-726; advance online publication, October 5, 2011; 10.1038/clpt.2011.204 Full Text TRANSLATION StaR Child Health: Developing Evidence-Based Guidance for the Design, Conduct, and Reporting of Pediatric Trials L Hartling, K D M Wittmeier, P H Caldwell, J H van der Lee, T P Klassen, J C Craig and M Offringa for the StaR Child Health group (http://www.starchildhealth.org) Clin Pharmacol Ther 2011 90: 727-731; advance online publication, October 12, 2011; 10.1038/clpt.2011.212 Abstract | Full Text Blinding in Randomized Clinical Trials: Imposed Impartiality A Hróbjartsson and I Boutron Clin Pharmacol Ther 2011 90: 732-736; advance online publication, October 12, 2011; 10.1038/clpt.2011.207 Abstract | Full Text DEVELOPMENT Developing a Valid Patient-Reported Outcome Measure N E Rothrock, K A Kaiser and D Cella Clin Pharmacol Ther 2011 90: 737-742; advance online publication, October 5, 2011; 10.1038/clpt.2011.195 Full Text The Patient-Reported Outcome (PRO) Consortium: Filling Measurement Gaps for PRO End Points to Support Labeling Claims S J Coons, S Kothari, B U Monz and L B Burke Clin Pharmacol Ther 2011 90: 743-748; advance online publication, October 12, 2011; 10.1038/clpt.2011.203 Abstract | Full Text Advertisement A personalized experience in clinical trial publishing. Network with Pharma Solutions on Linked In. Our group connects key decision makers in clinical trial publishing, including lead investigators, pharmaceutical companies, and medical communication agencies. Join in discussions and hot topics shaping the industry.   Please note that you need to be a subscriber or site-license holder to enjoy full-text access to Clinical Pharmacology & Therapeutics. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.